HCPCS Level II code J9040 represents an injection of bleomycin sulfate in 15-unit increments, a parenteral antineoplastic agent used in oncology. Nationally, accurate coding of drug J-codes is essential for claims processing, clinical tracking, and cost management for cancer therapies. This code matters because it standardizes billing for a cytotoxic agent that may be used across multiple malignancies and care settings.

Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of how the code is used clinically and operationally, typical sites of service where the drug is administered, and the payers most commonly involved in coverage decisions. The publication summarizes available benchmarks, identifies common billing and documentation considerations, and flags areas where policy updates or payer edits commonly appear.

This briefing is intended for billing managers, revenue cycle teams, oncology clinicians, and policy analysts seeking concise guidance about the clinical and administrative context of HCPCS Level II code J9040. Data not available in the input will be noted where applicable.